Biosimilars Rheumatology Roundup for February 2024—Podcast Edition

On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.

Show notes

FDA Approves 10th Adalimumab Biosimilar, Simlandi

Samsung Bioepis Announces New Biosimilar Partnership, Regulatory Updates

Vizient Report Emphasizes Biosimilar Successes, Impact of Inflation on Drug Spend

Eye on Pharma: VA Picks Hadlima; Biocon, Sandoz Partnership; A Stelara Settlement Abroad

Eye on Pharma: Celltrion Biosimilars Win Tenders; Oral Ustekinumab Device Passes Phase 1 Trial

Analyzing Safety of Switching From Originators to Biosimilars: A Meta-Analysis of 21 Trials

Adalimumab Treatment May Impact Antibody Levels After COVID-19 Vaccination